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Editorial
The crucial roles of Enzymes belonging to signal transduction
pathways. Old molecules as new therapy molecular targets.
Approaches, perspectives and criticisms.
Since last ten years the observation that most of the human
diseases can be considered “signaling diseases” was
corroborated by many reports. In this perspective, increasing
evidences demonstrated a crucial role for “signaling enzymes”,
the wide number of enzymes involved in specific steps of signal
transduction pathways. Many different families of enzymes are
involved in a variety of signal transduction pathways. In a
signaling system, enzymes are main actors which play important
roles, regulating the metabolism and concentration of further
signaling molecules. Thus, different families of enzymes regulate
a wide number of cell or tissue activities. As one example,
enzymes belonging to the Phosphoinositide-specific
Phospholipase C (PLC) family were reported to be involved in
many key functions such as intra-cellular signaling, membrane
trafficking, nuclear signaling based on lipid hydrolysis in
response to a wide panel of stimuli, including growth factors,
hormones, and neurotransmitters, that act on specific receptors
localized at the plasma membrane.
More recently, specific signal transduction pathways were
reported to be involved in human diseases. Following those
numerous and randomly distributed repots, cell or animal
models were developed evaluate the role, involved molecules
and meaning of the disruption of specific signal transduction
pathways. In this perspective, PLC enzymes were reported to be
associated to the transition from myelodysplastic syndrome to
acute myeloid leukemia, to different tumors, both in humans
and in animal models, to nervous diseases, including tumors,
schizoaffective disorders, mental retardation, as well as epileptic
encephalopathy, to cardiac problems, and skin disorders.
PLC enzymes belong to the phosphoinositide (PI) signal
transduction pathway. All PLC isoenzymes share the same main
activity. Activation of a PLC enzyme leads to cleavage of the
phosphatidyl inositol 4,5 bisphosphate (PIP2), a crucial molecule
in the PI system, located in the inner half of the cell membrane.
Cleaving of the polar head of PIP2 triggers the production of two
further signaling molecules, Diacylglycerol (DAG) and Inositol
trisphosphate (IP3). Although all PLC enzymes act cleaving PIP2,
the activation differs. Therefore, each isoenzyme probably bears
unique functions, related to the different mechanisms of
activation. Thus, the mammalian PLC family of enzymes,
comprising of 13 isoenzymes, was subdivided into 6 subfamilies,
differing for specific domains’ presence and activation stimuli.
Each subfamily comprises of isoenzymes sharing similar
aminoacids sequence, domain organization, and mechanisms of
activation. The distribution of the PLC enzymes is strictly tissue
specific. Each cytotype/histotype does not contain all 13 PLCs.
On the contrary, each cell/tissue owns a specific panel of PLC
enzymes. Moreover, the distribution of PLC enzymes was
demonstrated to vary in pathological cells/tissues with respect
to the normal counterpart. Different distribution of PLC enzymes
was also reported in activated cells with respect to the quiescent
counterpart, with special regard to inflammatory activated
endothelial cells, astrocytes and macrophages.
Specific inhibitors are currently available for most enzyme
families and, for a limited number, also activators can be used.
Therefore, the possibility to block (or activate) selected enzymes
offers the ability to control, regulate or modulate the activity of
the whole signal transduction pathway the enzyme belongs to
or, at least, to act upon a part of the system. For PLC enzymes,
the use of specific activators or inhibitors of the enzymatic
activity demonstrated a variation in the survival of cells or in the
sub-cellular distribution of the enzymes. More recently, also
epigenetic related methodologies (i.e. RNA silencing) allowed
control signaling related enzymes. For PLC enzymes, blocking
selected PLC isoenzymes, namely PLC, was demonstrated to
cells.
Thus, to affect a signal transduction pathway blocking its
enzymes can pave the way to molecular understanding of the
pathogenesis of the disease. Moreover, it can open the way to
novel therapeutic strategies, using the enzymes as molecular
targets.
Limitations of this promising perspective can be represented
by possible molecular switch of the pathway or trespassing the
block, limited action due to the time-dependent activity of the
inhibitors (or activators),
translation observations.
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However, beside those criticisms,
encouraging, also following the observation that inhibitors can
also affect the gene expression of enzymes suggesting a longer-
term activation.
Further studies are required in order to widen the knowledge
of the disruption of signal transduction pathways in human
diseases. New efforts are also required in order to evaluate the
time related effects and kinetics of the modulators (inhibitors
and activators) of signal transduction pathways with respect to
related human diseases.
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